New diagnostic and therapeutic possibilities for diastolic heart failure.
Despite the fact that up to half of all heart failure occurs in patients without evidence of systolic cardiac dysfunction, there are no universally accepted diagnostic markers and no approved therapies for heart failure with preserved ejection fraction (HFpEF). HFpEF, otherwise known as diastolic heart failure, has nearly the same grim prognosis as systolic heart failure, and diastolic heart failure is increasing in incidence and prevalence. Major trials have shown that many of the treatments that are salutary in systolic heart failure have no beneficial effects in diastolic heart failure, suggesting different underlying mechanisms for these two disorders. Even criteria for diagnosis of HFpEF are still debated, and there is still no gold standard marker to detect diastolic dysfunction. Here, we will review some promising new insights into the pathogenesis of diastolic dysfunction that may lead to new diagnostic and therapeutic tools.
Assistant Professor of Medicine (Research) at The Cardiovascular Research Center (CVRC) at the Department of Medicine, Rhode Island Hospital and the Warren Alpert Medical School of Brown University.
Euy-Myoung
EM
Jeong
Chief of Cardiology, The Miriam and Rhode Island Hospitals and Brown University; Director, Lifespan Cardiovascular Institute; and the Ruth and Paul Levinger Professor of Cardiology, The Warren Alpert Medical School of Brown University.
Samuel C
SC
Dudley
D054144:Heart Failure, Diastolic / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans
diabetes; diastolic dysfunction; heart failure; hypertension; oxidative stress